Selected article for: "adjuvant type and immune response"

Author: Wang, Jieliang; Peng, Ying; Xu, Haiyue; Cui, Zhengrong; Williams , Robert O.
Title: The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
  • Cord-id: ld4z4emp
  • Document date: 2020_8_5
  • ID: ld4z4emp
    Snippet: In the race for a safe and effective vaccine against coronavirus disease (COVID)-19, pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases. The proper choice of the type of vaccine, carrier or vector, adjuvant, excipients, dosage form, and route of administration can directly impact not only the immune responses induced and the resultant efficacy against COVID-19, but also the logistics of manufacturing, storing a
    Document: In the race for a safe and effective vaccine against coronavirus disease (COVID)-19, pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases. The proper choice of the type of vaccine, carrier or vector, adjuvant, excipients, dosage form, and route of administration can directly impact not only the immune responses induced and the resultant efficacy against COVID-19, but also the logistics of manufacturing, storing and distributing the vaccine, and mass vaccination. In this review, we described the COVID-19 vaccines that are currently tested in clinical trials and provided in-depth insight into the various types of vaccines, their compositions, advantages, and potential limitations. We also addressed how challenges in vaccine distribution and administration may be alleviated by applying vaccine-stabilization strategies and the use of specific mucosal immune response-inducing, non-invasive routes of administration, which must be considered early in the development process.

    Search related documents:
    Co phrase search for related documents
    • active ingredient and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activity stability and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute sars respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute sars respiratory syndrome coronavirus and adaptive immune system activate: 1
    • acute sars respiratory syndrome coronavirus and adherent cell: 1, 2, 3, 4
    • acute sars respiratory syndrome coronavirus and adherent cell line: 1